<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50471">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02157129</url>
  </required_header>
  <id_info>
    <org_study_id>HNO-TUM-LT1</org_study_id>
    <nct_id>NCT02157129</nct_id>
  </id_info>
  <brief_title>Efficacy of LipoAerosol© in Patients After Tracheostomy</brief_title>
  <acronym>LipoTrach</acronym>
  <official_title>Efficacy of LipoAerosol© in Patients After Tracheostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients after tracheostomy represent a substantial part in the ear nose throat clinic. In
      addition, long-term intubated patients in intensive care units profit from tracheostomy due
      to an improved respiratory toilet. However, after tracheostomy patients demonstrate shunt
      ventilation bypassing the sinonasal and the pharyngeal system. The physiological moistening,
      cleaning and warming of the breathing air fail resulting in a local respiratory
      inflammation. Beside a variety of supportive medical devices with different mechanisms of
      action no general recommendation exists at present.  Recently, we demonstrated the
      beneficial application of local phospholipids in Sjoegren's syndrome and antineutrophil
      cytoplasmatic antibody associated sinonasal vasculitis.

      In the current monocentric, two-armed, double-blinded, randomized parallel group study we
      would like to evaluate the beneficial application of LipoAerosol© when compared with
      standard physiologic saline inhalation. LipoAerosol© is a licensed, tradable medical device
      and will be applied as part of its intended use. Liposomal inhalation solution provides
      moistening, cleaning and warming of the upper and lower respiratory tract and supports the
      natural moistening film in airway irritations and diseases.

      Blood parameter (leucocytes and c reactive protein) and tracheobronchial secretion
      (Lymphocyte subpopulation, c reactive protein, lactate dehydrogenase, granulocyte macrophage
      colony stimulating factor, interferon γ, interleukins 10, 12 (p70), 13, 1β, 2, 4, 5, 6, 7,
      8, tumor necrosis factor α) will be collected 1, 3, and 10 days after tracheostomy. In
      addition, medical examination records the number of suction maneuver (0 points: none; 1
      point: 5-10x/d; 2 points: 10-20x/d; 3 points: &gt;20x/d), flexible-optical assessment of
      tracheo-bronchial redness (0 point: none; 1 point: peristomal; 2 points: tracheal; 3 points:
      tracheo-bronchial) and flexible-optical assessment of mucous congestion (0 point: none; 1
      point: fluent; 2 points: tenacious; 3 points: barky).

      Subjective estimation of the respiratory impairment will be analyzed via visual analogue
      scale (Subjective overall impairment, coughing frequency, breathlessness, mucous congestion,
      color of sputum, consistency of sputum). The study is designed without any additional
      invasive or incriminating clinical examination.

      Aim of the study is the effective symptom reduction after tracheostomy using LipoAerosol©
      resulting in a general therapeutic recommendation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Changes in the number of suction maneuver, tracheo-bronchial redness, and mucous congestion</measure>
    <time_frame>at day 3 after tracheostomy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in the respiratory impairment due to the medical estimation at day 3. The medical estimation includes number of suction maneuver (0 points: none; 1 point: 5-10x/d; 2 points: 10-20x/d; 3 points: &gt;20x/d), flexible-optical assessment of tracheo-bronchial redness (0 point: none; 1 point: peristomal; 2 points: tracheal; 3 points: tracheo-bronchial) and flexible-optical assessment of mucous congestion (0 point: none; 1 point: fluent; 2 points: tenacious; 3 points: barky).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the number of suction maneuver, tracheo-bronchial redness, and mucous congestion</measure>
    <time_frame>at day 10 after tracheostomy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in the respiratory impairment due to the medical estimation at day 10. The  medical estimation includes number of suction maneuver (0 points: none; 1 point: 5-10x/d; 2 points: 10-20x/d; 3 points: &gt;20x/d), flexible-optical assessment of tracheo-bronchial redness (0 point: none; 1 point: peristomal; 2 points: tracheal; 3 points: tracheo-bronchial) and flexible-optical assessment of mucous congestion (0 point: none; 1 point: fluent; 2 points: tenacious; 3 points: barky).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the inflammatory blood and tracheal secretion parameters</measure>
    <time_frame>at day 1, 3, 10 after tracheostomy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood: C reactive protein, leucocytes Tracheal secretion: Lymphocyte subpopulation, c reactive protein, lactate dehydrogenase, granulocyte macrophage colony stimulating factor, interferon γ, interleukins 10, 12 (p70), 13, 1β, 2, 4, 5, 6, 7, 8, tumor necrosis factor α</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the subjective overall impairment, coughing frequency, breathlessness, mucous congestion, color of sputum, consistency of sputum on the visual analogue scale</measure>
    <time_frame>at day 1, 3, 10 after tracheostomy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjective estimation of the respiratory impairment will be analyzed via visual analogue scale (Subjective overall impairment, coughing frequency, breathlessness, mucous congestion, color of sputum, consistency of sputum).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Respiratory Inflammation After Tracheostomy</condition>
  <arm_group>
    <arm_group_label>LipoAerosol©</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LipoAerosol© inhalation, 5x/d for 30min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiologic saline inhalation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Physiologic saline inhalation, 5x/d for 30min</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipoAerosol© inhalation</intervention_name>
    <description>LipoAerosol© inhalation, 5x/d for 30min</description>
    <arm_group_label>LipoAerosol©</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiologic saline inhalation</intervention_name>
    <description>Physiologic saline inhalation, 5x/d for 30min</description>
    <arm_group_label>Physiologic saline inhalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients after recent tracheostomy

        Exclusion Criteria:

          -  Patients with existing tracheostoma

          -  Patients with acute or imminent sepsis

          -  Patients with existing bronchopulmonary inflammation Patients with immunosuppressive
             therapy

          -  Patients with poorly adjusted pulmonary disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Knopf, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HNO, Klinikum rechts der Isar, TU München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Knopf, PD Dr.</last_name>
    <phone>0049-89-4140</phone>
    <phone_ext>5383</phone_ext>
    <email>a.knopf@lrz.tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Murat Bas, PD Dr.</last_name>
    <phone>0049-89-4140</phone>
    <phone_ext>5380</phone_ext>
    <email>m.bas.hno@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HNO, Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Knopf, PD Dr.</last_name>
      <phone>0049-89-4140</phone>
      <phone_ext>5383</phone_ext>
      <email>a.knopf@lrz.tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Murat Bas, PD Dr.</last_name>
      <phone>0049-89-4140</phone>
      <phone_ext>5380</phone_ext>
      <email>m.bas.hno@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Strassen, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lena Lenschow</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benedikt Hofauer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Wirth, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Braun A, Steinecker M, Schumacher S, Griese M. Surfactant function in children with chronic airway inflammation. J Appl Physiol (1985). 2004 Dec;97(6):2160-5. Epub 2004 Aug 13. PubMed</citation>
    <PMID>15310745</PMID>
  </reference>
  <reference>
    <citation>Hofauer B, Bas M, Straßen U, Matsuba Y, Mansour N, Knopf A. [Liposomal Local Therapy of Sinunasal Symptoms in ANCA Associated Vasculitis.]. Laryngorhinootologie. 2014 Apr 28. [Epub ahead of print] German. PubMed</citation>
    <PMID>24777579</PMID>
  </reference>
  <reference>
    <citation>Hofauer B, Bas M, Manour N, Knopf A. [Liposomal local therapy as treatment for sicca symptoms in patients with primary Sjögren's syndrome]. HNO. 2013 Nov;61(11):921-7. doi: 10.1007/s00106-013-2736-x. German. PubMed</citation>
    <PMID>23868654</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tracheostomy</keyword>
  <keyword>inflammation</keyword>
  <keyword>mucous congestion</keyword>
  <keyword>inhalation therapy</keyword>
  <keyword>phospholipids</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
